Failure Mode Identification of Insulin Drug Products - Impact of Relevant Stress Conditions on the Quality of the Drug

J Pharm Sci. 2022 Sep;111(9):2451-2457. doi: 10.1016/j.xphs.2022.06.013. Epub 2022 Jun 23.

Abstract

Fast-acting insulin drug products (DPs) are carried and administered by diabetic patients to maintain their blood glucose level throughout the day, exposing the DPs to stress conditions. Apidra, Novolog, and Humalog insulin DPs were tested under various stress conditions. Dynamic light scattering (DLS), and size exclusion chromatography (SEC) were used to monitor the stability and aggregation. Thermal stress alone did not influence the stability. However, 24 hr exposure to vigorous mechanical stress shifted the DLS size peaks of Novolog and Humalog from 5 ± 1 nm to > 50.9 ± 25.6 nm, and the SEC native protein peak areas decreased 52% for Novolog and 18.4% for Humalog. Combined stress accelerated protein aggregation more drastically. Novolog and Humalog size shifted (>75 nm) after 3 hr and the peak area decreased > 97.9% after 6 hr exposure, indicating that high temperature accelerated the aggregation triggered by agitation. Soluble aggregates were captured by DLS early on compared to SEC. Apidra was comparably stable indicating DP formulation plays a critical role in stability. Our study provides a greater understanding of potential failure modes patients and care givers may encounter while handling insulin DPs.

Keywords: Biopharmaceutical characterization; Insulin; Light scattering (dynamic); Polysorbate; Protein aggregation; Size exclusion chromatography; Stability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatography, Gel
  • Dynamic Light Scattering
  • Humans
  • Insulin Aspart*
  • Insulin Lispro
  • Protein Aggregates*

Substances

  • Insulin Lispro
  • Protein Aggregates
  • Insulin Aspart